You are here

Talzenna

Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC

Clinical Trials Arena

Tue, 02/18/25 - 09:49 am

prostate cancer

clinical trials

Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval

Fierce Pharma

Thu, 02/13/25 - 11:43 am

prostate cancer

Pfizer's cancer drug combo improves overall survival in late-stage study

Reuters

Thu, 10/10/24 - 09:59 am

prostate cancer

Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med

Fierce Pharma

Thu, 06/22/23 - 10:12 am

prostate cancer

PARP inhibitors

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

Endpoints

Tue, 10/4/22 - 11:06 am

PARP inhibitors

clinical trials

prostate cancer

ASCO-GU – prostate cancer PARPS move to the front line

EP Vantage

Sun, 02/20/22 - 11:44 am

prostate cancer

PARP inhibitors

Clovis Oncology

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

BioCentury

Tue, 11/6/18 - 11:35 am

Nektar Therapeutics

prostate cancer

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Fierce Pharma

Thu, 10/18/18 - 12:15 am

PARP inhibitors